vaccin
sever
acut
respiratori
syndrom
sar
intens
pursu
reemerg
gener
sar
coronaviru
sarscov
spike
proteinexpress
recombin
vaccinia
viru
rvv
use
highli
attenu
strain
intraderm
administr
rvv
rabbit
induc
neutral
nt
antibodi
sarscov
week
administr
nt
titer
reach
boost
immun
rvv
significantli
nt
antibodi
sarscov
induc
administr
rvv
rabbit
preimmun
rvv
induc
nt
antibodi
sarscov
despit
presenc
nt
antibodi
vv
result
suggest
rvv
may
power
sar
vaccin
includ
patient
previous
immun
smallpox
vaccin
novemb
influenzalik
acut
pneumonia
design
sever
acut
respiratori
syndrom
sar
world
health
organ
first
emerg
china
spread
countri
within
month
juli
probabl
case
death
report
wwwcdcgovmmwrmguid
sarshtml
etiolog
agent
sar
identifi
novel
type
coronaviru
cov
genet
distinct
previous
character
member
coronavirida
famili
like
coronavirus
sarscov
posit
strand
rna
viru
approxim
kb
genom
encod
nonstructur
protein
well
structur
protein
includ
spike
envelop
membran
nucleocapsid
spike
protein
type
transmembran
glycoprotein
mediat
bind
host
cell
receptor
use
aminotermin
domain
membran
fusion
use
carboxyltermin
domain
angiotensinconvert
enzym
bind
domain
sarscov
spike
protein
function
receptor
sarscov
cov
spike
protein
major
target
protect
immun
neutral
nt
antibodi
cytotox
lymphocyt
sarscov
spike
protein
detect
sar
patient
find
indic
sarscov
spike
protein
appropri
target
vaccin
therapi
sar
epidem
broke
may
howev
sever
case
sar
report
china
although
civet
cat
bat
suspect
natur
host
sarscov
reservoir
sarscov
yet
identifi
addit
precis
mechan
underli
develop
sar
clear
therapeut
guidelin
sar
establish
report
prophylact
therapeut
treatment
pegyl
reduc
viral
replic
excret
sarscov
infect
macaqu
although
pegyl
may
eventu
becom
good
therapeut
agent
sar
infect
provid
longterm
protect
use
prophylact
agent
therefor
develop
sar
vaccin
imper
sever
group
report
number
sar
vaccin
candid
includ
inactiv
sarscov
vaccin
dna
vaccin
recombin
viral
vaccin
express
one
sarscov
structur
protein
recombin
live
viral
vaccin
gener
induc
strong
longterm
immun
similar
attenu
live
vaccin
abundantli
manufactur
short
period
time
importantli
safe
vaccin
develop
use
attenu
strain
alreadi
proven
safe
vaccinia
viru
vv
doubl
strand
dna
viru
kb
genom
attenu
strain
use
smallpox
vaccin
long
dna
fragment
abl
insert
vv
genom
homolog
recombin
without
damag
viral
integr
vv
genom
larg
contain
gene
nonessenti
viral
replic
fact
recombin
vv
express
variou
protein
encod
transduc
gene
includ
glycosyl
protein
pathogen
evalu
candid
prophylact
therapeut
vaccin
lister
attenu
vv
strain
use
worldwid
smallpox
erad
program
howev
addit
attenu
strain
gener
lister
due
side
effect
includ
erythema
fever
enceph
isol
lister
via
intermedi
strain
multipl
plaqu
purif
primari
rabbit
kidney
cell
character
temperatur
sensit
format
small
pock
seriou
side
effect
observ
among
peopl
immun
immunogen
similar
lister
therefor
author
vaccin
smallpox
japanes
ministri
health
welfar
recombin
vv
express
protein
encod
transduc
gene
control
promot
highli
effici
hybrid
promot
develop
compos
poxviru
atyp
inclus
bodi
ati
late
promot
tandem
repeat
mutat
kda
protein
earli
promot
protein
express
control
hybrid
promot
strongli
induc
humor
cellular
immun
present
studi
gener
recombin
vv
express
sarscov
spike
protein
rvv
control
hybrid
promot
use
examin
whether
rvv
could
use
sar
vaccin
sarscov
strain
isol
nasal
throat
swab
patient
hanoi
previous
describ
kindli
provid
chemoserotherapeut
research
institut
kumamoto
japan
cell
line
atcc
vero
cell
line
atcc
cultur
mem
nissui
pharmaceut
co
ltd
tokyo
japan
contain
fetal
bovin
serum
vector
contain
hybrid
promot
within
hemagglutinin
ha
gene
region
vv
full
length
cdna
encod
sarscov
spike
protein
gene
clone
sarscov
viral
rna
rtpcr
insert
downstream
hybrid
promot
final
design
transfect
cell
infect
multipl
infect
moi
plaqu
form
unit
pfu
cell
h
transfect
viru
harvest
ha
neg
plaqu
clone
describ
previous
briefli
harvest
viru
reinfect
cell
h
infect
cell
wash
pb
twice
incub
chicken
erythrocyt
min
c
follow
wash
pb
white
plaqu
isol
isol
virus
clone
three
serial
round
plaqu
purif
use
erythrocyt
agglutin
propag
cell
insert
sarscov
spike
protein
gene
genom
confirm
direct
pcr
express
detect
western
blot
viral
titer
rvv
determin
use
standard
plaqu
assay
cell
infect
rvv
moi
h
infect
cell
lyse
ripa
buffer
mm
tri
ph
mm
nacl
sd
g
total
protein
subject
sdspage
transfer
polyvinyliden
difluorid
membran
immobilonp
millipor
bedford
membran
block
skim
milk
tb
contain
tbst
wash
tbst
polyclon
antibodi
spike
protein
use
primari
antibodi
prepar
rabbit
sera
immun
klhconjug
spike
protein
peptid
amino
acid
residu
igg
fraction
purifi
use
ampur
pa
kit
amersham
bioscienc
piscataway
nj
antigenantibodi
interact
detect
horseradish
peroxidas
hrp
conjug
donkey
antirabbit
polyclon
antibodi
amersham
bioscienc
visual
use
ecl
system
amersham
bioscienc
cell
seed
slideglass
infect
rvv
moi
h
incub
c
cell
fix
cold
acetonemethanol
block
bsa
pb
h
room
temperatur
follow
remov
block
buffer
cell
incub
polyclon
antibodi
spike
protein
recogn
ctermin
peptid
spike
protein
amino
acid
residu
h
room
temperatur
follow
three
wash
pb
contain
pbst
cell
incub
alexa
antirabbit
igg
invitrogen
carlsbad
ca
h
room
temperatur
wash
pbst
slideglass
mount
permafluor
beckman
coulter
fullerton
ca
contain
gml
dapi
analyz
use
confoc
microscop
carl
zeiss
oberkochen
germani
group
three
new
zealand
white
rabbit
purchas
slc
hamamatsu
japan
intraderm
immun
one
sever
dose
pfu
rvv
pfu
week
immun
group
immun
pfu
rvv
week
anoth
group
three
rabbit
immun
pfu
week
immun
pfu
rvv
week
summari
immun
schedul
shown
tabl
sera
collect
everi
week
use
enzym
link
immunosorb
assay
elisa
vitro
neutral
nt
assay
anim
experi
approv
tokyo
metropolitan
institut
medic
scienc
anim
experi
committe
perform
accord
anim
experiment
guidelin
tokyo
metropolitan
institut
medic
scienc
full
length
recombin
sarscov
spike
protein
contain
sixhistidin
tag
express
cell
rvvshi
gener
purifi
use
nickel
sepharos
amersham
bioscienc
peptid
ntermin
mixtur
three
peptid
amino
acid
residu
middl
posit
mixtur
two
peptid
amino
acid
residu
ctermin
mixtur
three
peptid
amino
acid
residu
spike
protein
respond
sera
sarsinfect
individu
purchas
prospectani
technogen
ltd
rehovot
israel
three
peptid
mixtur
full
length
spike
protein
coat
onto
well
plate
c
plate
block
bsa
pb
contain
mm
edta
incub
serial
dilut
sera
rabbit
immun
rvv
extens
wash
plate
incub
hrpconjug
donkey
antirabbit
polyclon
antibodi
amersham
bioscienc
antigenantibodi
interact
detect
use
tetramethylbenzidin
solut
substrat
becton
dickinson
san
jose
ca
bind
activ
measur
absorb
nm
serial
dilut
heatinactiv
sera
mix
equal
volum
tcid
sarscov
incub
c
h
vero
cell
infect
virussera
mixtur
well
plate
h
infect
nt
titer
determin
maximum
dilut
sera
inhibit
sarscov
induc
cytopath
effect
experi
sarscov
perform
biosafeti
contain
level
iii
facil
serial
dilut
heatinactiv
sera
mix
equal
volum
pfu
incub
c
h
follow
incub
c
h
cell
infect
virussera
mixtur
well
plate
h
infect
nt
titer
determin
maximum
dilut
sera
inhibit
plaqu
format
data
express
mean
sem
data
rvv
dose
depend
effect
statist
analyz
oneway
anova
follow
turkey
test
data
preimmun
effect
statist
analyz
student
welch
ttest
p
consid
statist
signific
full
length
sarscov
spike
protein
gene
insert
homolog
recombin
ha
gene
region
locat
downstream
power
hybrid
promot
fig
recombin
result
inactiv
ha
gene
screen
rvv
use
erythrocyt
agglutin
assay
insert
transduc
gene
confirm
pcr
confirm
express
sarscov
spike
protein
western
blot
perform
two
kind
rabbit
polyclon
antibodi
recogn
differ
epitop
amino
acid
residu
sarscov
spike
protein
use
primari
antibodi
rvv
infect
cell
antibodi
detect
approxim
kda
protein
fig
c
consist
molecular
mass
spike
protein
sarscov
spike
protein
report
highli
glycosyl
thu
molecular
mass
sdspage
larger
predict
gene
sequenc
express
spike
protein
follow
infect
rvv
also
confirm
immunofluoresc
analysi
rvv
infect
vero
cell
stain
antibodi
spike
protein
wherea
stain
observ
cell
infect
uninfect
control
cell
fig
investig
whether
rvv
induc
bind
antibodi
spike
protein
pfu
rvv
control
intraderm
inject
rabbit
week
rabbit
immun
either
rvv
exhibit
weight
loss
clinic
sign
except
region
skin
reaction
erythema
indur
skin
reaction
induc
rvv
compar
induc
data
shown
bind
antibodi
full
length
spike
protein
detect
elisa
sera
rabbit
immun
rvv
fig
next
investig
bind
activ
immun
sera
differ
epitop
spike
protein
rvvsimmun
sera
react
three
region
spike
protein
sera
bound
ctermin
peptid
contain
heptad
repeat
region
report
nt
epitop
sarscov
fig
middl
peptid
receptor
bind
domain
anoth
nt
epitop
sarscov
includ
next
determin
whether
antibodi
induc
immun
rvv
nt
activ
sarscov
perform
vitro
nt
assay
sarscov
use
immun
sera
interestingli
sera
obtain
three
rabbit
group
show
nt
activ
sarscov
even
week
immun
pfu
rvv
fig
nt
titer
reach
week
increas
boost
immun
contrast
sera
obtain
rabbit
immun
show
nt
activ
sarscov
fig
next
determin
minimum
dose
induc
nt
antibodi
sarscov
singl
immun
rabbit
immun
lower
dose
rvv
three
rabbit
underw
singl
immun
pfu
rvv
gener
nt
antibodi
sarscov
fig
nt
titer
increas
boost
immun
pfu
rvv
reach
compar
level
induc
pfu
rvv
fig
hand
nt
activ
induc
singl
immun
pfu
rvv
week
immun
three
rabbit
decreas
detect
limit
one
rabbit
week
fig
howev
nt
titer
increas
approxim
group
immun
pfu
rvv
boost
immun
dose
rvv
fig
induct
nt
antibodi
vv
rvv
next
examin
vitro
nt
assay
vv
reveal
rvv
equal
induc
nt
antibodi
vv
rabbit
fig
nt
activ
vv
induc
pfu
rvv
week
immun
similar
sarscov
nt
titer
vv
reach
week
boost
immun
pfu
rvv
similar
induc
pfu
result
suggest
epitop
nt
antibodi
vv
preserv
rvv
sinc
vv
use
smallpox
vaccin
human
concern
rvv
might
elimin
host
immun
respons
induc
effect
immun
protein
encod
transduc
gene
therefor
assess
whether
rvv
induc
nt
antibodi
sarscov
rabbit
nt
antibodi
vv
rvv
inject
rabbit
preimmun
nt
antibodi
vv
induc
rabbit
singl
immun
pfu
nt
titer
reach
fig
follow
immun
equal
dose
rvv
pfu
nt
antibodi
sarscov
induc
three
rabbit
although
induct
nt
antibodi
delay
one
rabbit
although
induct
nt
antibodi
sarscov
partial
suppress
preimmun
rabbit
nt
titer
increas
three
rabbit
boost
immun
rvv
fig
result
suggest
rvv
induc
nt
antibodi
individu
previous
immun
smallpox
vaccin
next
examin
whether
rvv
induc
nt
antibodi
sarscov
rabbit
high
titer
nt
antibodi
vv
nt
titer
vv
rabbit
immun
twice
pfu
sustain
approxim
fig
although
rabbit
extrem
high
titer
nt
antibodi
vv
nt
antibodi
sarscov
induc
three
rabbit
upon
booster
inject
pfu
rvv
fig
surprisingli
nt
titer
rabbit
increas
level
compar
nonpreimmun
rabbit
fig
result
indic
immun
respons
protein
encod
transduc
gene
induc
immun
pfu
rvv
spite
preexist
nt
antibodi
vv
present
studi
gener
sarscov
spike
proteinexpress
recombin
vaccinia
viru
use
highli
attenu
strain
demonstr
nt
antibodi
sarscov
strongli
induc
immun
rvv
rabbit
also
preimmun
rabbit
previou
studi
passiv
transfer
sera
obtain
mice
inocul
sarscov
prevent
replic
sarscov
upper
lower
respiratori
tract
addit
intraperiton
inject
sera
mice
immun
mva
express
spike
protein
mva
reduc
viral
titer
lung
nasal
turbin
dosedepend
manner
find
indic
nt
antibodi
spike
protein
suffici
protect
sarscov
infect
singl
immun
pfu
rvv
two
immun
pfu
rvv
abl
induc
high
level
nt
antibodi
sarscov
week
immun
therefor
rvv
also
may
protect
sarscov
vivo
would
highli
effect
vaccin
sar
individu
contrari
studi
czub
et
al
report
immun
mva
prevent
sarscov
infect
ferret
rather
produc
inflammatori
respons
focal
necrosi
liver
sarscov
challeng
may
due
low
nt
activ
sarscov
induc
mva
immun
moreov
precis
mechan
liver
inflamm
clarifi
felin
infecti
periton
viru
fipv
anoth
member
coronavirus
exhibit
enhanc
fipv
infect
monocytesmacrophag
viralspecif
antibodi
bind
fc
receptor
cell
caus
enhanc
inflamm
howev
evid
nt
antibodi
sarscov
caus
antibodydepend
enhanc
correl
inflamm
antibodydepend
enhanc
mva
vaccin
yet
establish
side
effect
vaccin
also
influenc
dosag
rout
immun
czub
report
mva
intraperiton
inject
ferret
although
vaccin
rvv
conduct
rout
intraderm
intramuscular
subcutan
inject
therefor
select
differ
immun
rout
may
prevent
side
effect
nonetheless
analysi
side
effect
variou
sar
vaccin
includ
rvv
requir
vivo
sarscov
challeng
model
varieti
anim
use
rvv
candid
sar
vaccin
mean
possibl
complic
due
previou
vaccin
vv
smallpox
may
avoid
hammarlund
et
al
report
particular
antivir
antibodi
poxviru
maintain
long
time
possibl
life
immun
smallpox
vaccin
therefor
concern
rvv
vaccin
would
elimin
host
antivir
immun
respons
induct
effect
humor
andor
cellular
immun
protein
encod
transduc
gene
howev
immun
pfu
rvv
induc
nt
antibodi
sarscov
rabbit
immun
pfu
fig
induct
nt
antibodi
sarscov
rabbit
preimmun
three
rabbit
immun
pfu
day
immun
pfu
rvv
week
b
three
rabbit
immun
pfu
week
immun
pfu
rvv
week
immun
rabbit
sera
analyz
vitro
nt
assay
sarscov
close
symbol
vaccinia
viru
open
symbol
type
symbol
indic
one
individu
schedul
immun
rvv
indic
arrowhead
c
comparison
nt
antibodi
sarscov
induc
rvv
vvimmun
rabbit
rvv
pfu
inject
rabbit
week
presenc
pfu
pfu
absenc
pfu
pfu
preimmun
equal
titer
immun
rabbit
sera
analyz
vitro
nt
assay
sarscov
p
sinc
nt
titer
vv
induc
pfu
compar
peopl
vaccin
smallpox
vaccin
rvv
may
induc
nt
antibodi
sarscov
peopl
hand
pfu
rvv
also
induc
nt
antibodi
sarscov
rabbit
extrem
high
titer
nt
antibodi
vv
due
two
preimmun
pfu
furthermor
differ
nt
titer
sarscov
induc
rvv
rabbit
preimmun
rabbit
immun
respons
protein
encod
transduc
gene
may
influenc
amount
antigen
express
antigen
protein
encod
transduc
gene
rout
immun
viral
prolifer
host
thu
analysi
requir
resolv
precis
mechan
involv
furthermor
vaccin
effect
rvv
still
need
confirm
human
preimmun
smallpox
vaccin
present
studi
immun
rvv
manifest
vaccin
effect
sarscov
spite
preexist
nt
antibodi
vv
find
indic
rvv
vaccin
deriv
use
peopl
previous
immun
smallpox
vaccin
furthermor
rvv
vaccin
could
repeatedli
use
variou
microb
influenza
viru
alter
protein
encod
transduc
gene
therefor
use
rvv
vaccin
gener
promis
vaccin
strategi
variou
infecti
diseas
